Fecal Microbiota Transplantation for Kidney Stone Patients
Official title: Fecal Microbiota Transplantation (FMT CAPSULE DE, FMPCapDE, MTP-CP101) in Kidney Stone Patients (FMT IND STUDY)
Run by Intermountain Health Care, Inc. · NCT05516472 · Data updated 2026-11-12
This study is testing if a new treatment using healthy gut bacteria can help people with recurring kidney stones caused by high levels of calcium and oxalate in their urine.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 69 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Intermountain Health Care, Inc. Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Park City, Utah) |
| Status | Recruiting |
| Started | October 10, 2024 |
| Main results expected | December 2027 |
| Study ends | March 2028 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT05516472 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 70 with a history of kidney stones composed of at least 50% calcium-oxalate and specific urinary parameters indicating hypercalciuria or hyperoxaluria.
✕Probably not a fit
Patients with metabolic syndrome or those currently participating in other interventional kidney stone studies may not benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of Microbial Transplant Therapy (MTT) on urinary parameters in patients with recurrent kidney stones, specifically those with hypercalciuria and hyperoxaluria. Participants will undergo screening and baseline assessments, including a 24-hour urine collection to analyze various urinary components. The study will enroll 36 patients divided into four groups based on their urinary stone composition, with some receiving MTT and others receiving a placebo. Stool samples will also be collected for metagenomic analysis prior to the intervention.
Why it matters
Potential benefit: If successful, this approach could provide a novel treatment option for patients suffering from recurrent kidney stones.
How similar studies have gone: While the use of microbial transplant therapy is a novel approach in this context, similar studies in other conditions have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older and younger than 70 years. * Recent urinary stone disease with at least 50% calcium-oxalate composition confirmed by stone analysis. * 24-hour urinary calcium \>225 mg/day or urinary oxalate \>40 mg/day. * Able to provide informed consent. * Willing to complete safety follow-up, study visits, 24-hour urine collections, and serial stool collections. * Not actively participating in another interventional urinary stone disease trial. * eGFR \>=60. Exclusion Criteria: * Three or more NIH-defined metabolic syndrome features. * Any autoimmune disease or inflammatory bowel disease. * Major gastrointestinal surgery within 3 months, excluding appendectomy or cholecystectomy; history of total colectomy or bariatric surgery. * Primary or secondary hyperparathyroidism or PTH outside 15-65 pg/mL. * Pancreatic enzyme replacement, ongoing dialysis, or eGFR \<60. * Chemotherapy in the prior year or concurrent intensive cancer therapy. * Antibiotics within 3 months of study entry, continued antibiotic need, or anticipated antibiotic use in the next 4 weeks. * Unable to complete required washout from potassium citrate, thiazides, or proton pump inhibitors. * Pregnant, breastfeeding, or planning pregnancy during the study. * Unable or unwilling to swallow capsules, including CTCAE grade \>=2 dysphagia. * Active gastrointestinal infection, toxic megacolon, or small bowel ileus. * Life expectancy \<6 months. * Prior FMT or microbiome-based product outside this study. * Severe anaphylactic or anaphylactoid food allergy. * Solid organ transplant recipient. * Any condition jeopardizing safety or rights, preventing completion, or confounding results. * Urinary oxalate \>=80 mg/day.
Where it's running
-
Park City Hospital
Park City, Utah, United States Recruiting
Study contacts
- Principal investigator: Joshua Stern, MD — Intermountain Health Care, Inc.
- Study coordinator: Nic Unsworth
- Email: nic.unsworth@imail.org
- Phone: (801) 507-8280
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Modified Mini-PCNL vs Standard PCNL for Complex Kidney Stones
This study tests whether a smaller 20 Fr access in modified mini-PCNL can match the stone-clearing success of the standard 24 Fr PCNL in adults with complex kidney stones.
-
Aspirating vs non-aspirating ureteral access sheath in RIRS for kidney stones
This trial tests whether using an aspirating ureteral access sheath during retrograde intrarenal surgery improves stone clearance and reduces complications compared with a non-aspirating sheath in adults with small kidney stones.
-
Suction to collapse the kidney's collecting system after RIRS (retrograde intrarenal surgery)
This trial will test whether actively suctioning the kidney's collecting system at the end of RIRS reduces early postoperative pain and infections for adults having kidney stone removal.
-
Compare two suction ureteroscope devices for kidney stones (FANS vs CVAC)
This study tests whether two new suction-enabled ureteroscopes (FANS and CVAC) lead to better stone clearance for adults with small to medium kidney stones compared to each other.
-
Negative-pressure suction during flexible ureteroscopy to reduce fluid absorption and infections
This test will see if using a negative-pressure suction sheath during retrograde intrarenal surgery for adults with kidney stones reduces how much irrigation fluid their bodies absorb and lowers the risk of postoperative infections.
-
Outcomes and costs with the HugeMed 6.3 Fr flexible ureteroscope
This trial will test whether the HugeMed 6.3 Fr flexible ureteroscope gives similar stone-free results while lowering costs compared with traditional flexible ureteroscopes in adults having RIRS for stones up to 2.5 cm.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.